Recursion Pharmaceuticals
RXRX · NASDAQ · Healthcare
$3.70
$0.32 (-8.64%) today
Market Cap
$1.98B
24h Volume
$87.2M
P/E Ratio
-4.3
52w High
$6.79
52w Low
$2.84
Est. AI Revenue
85%
7-Day Sparkline (Static)
Company facts
Performance
About Recursion Pharmaceuticals
Recursion Pharmaceuticals is a clinical-stage TechBio company trying to industrialize drug discovery. It pairs AI with enormous automated biology experiments, generating its own datasets and using models to decode how biology works. Revenue comes from pharma partnerships and, eventually, its own drug pipeline.
Its stack includes Recursion OS, the operating system tying automated labs to machine learning, the LOWE and Boltz foundation models trained on biological data, and its broader AI drug discovery platform that proposes targets and molecules for testing.
Founded in 2013 and headquartered in Salt Lake City, Utah, Recursion trades on the NASDAQ and employs about 600 people under co-founder and CEO Najat Khan.
Recursion Pharmaceuticals in the AI buildout
Recursion sits in the AI Healthcare and Foundation Models layers as one of the clearest AI-native bets in biotech. It trains biological foundation models on datasets its own automated labs generate, releasing work such as the Boltz co-folding models openly while monetizing through pharma partnerships and its own pipeline. That makes AI the company rather than a tool inside it, which is why Supercycle scores its AI exposure at 90 out of 100.
RXRX is tracked in AI Healthcare and Foundation Models, rated Pure Play on the AI Exposure leaderboard.
By the numbers
52-week range
RXRX trades at $3.70, 22% of the way up its 52-week range of $2.84 to $6.79.
Market cap
Market capitalization is $1.98B, with an AI Exposure Score of 90 out of 100.
Next earnings
Recursion Pharmaceuticals is next expected to report earnings on November 4, 2026.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does Recursion Pharmaceuticals do?
Recursion is a clinical-stage TechBio company that industrializes drug discovery. It runs massive automated biology experiments, trains AI models on the resulting data, and monetizes through pharma partnerships and its own pipeline.
How is Recursion exposed to AI?
Almost entirely. The company is built as a bet that AI can decode biology, with foundation models and automated datasets at the core of everything it does. Supercycle rates its AI Exposure Score at 90 out of 100.
What are Recursion's main products?
Recursion OS, the platform connecting its automated labs to machine learning, LOWE foundation models trained on biological data, and its AI drug discovery platform for proposing targets and molecules.
Is RXRX a pure play AI stock?
Yes by Supercycle's rating. Recursion exists as an AI-first drug discovery bet, and its AI Exposure Score of 90 out of 100 places it in the top tier of the exposure leaderboard.
Where is Recursion based and who leads it?
Recursion is headquartered in Salt Lake City, Utah, and led by co-founder and CEO Najat Khan. Founded in 2013, the company employs about 600 people and its shares trade on the NASDAQ.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.